+1 (855) PLE.XISION (753.9474) info@plexision.com
PERSONALIZED MEDICINE FOR BETTER HEALTH

FDA approves PleximmuneTM for personalized prediction of transplant rejection in children

You are here

Home    /    Blog    /    FDA approves PleximmuneTM for personalized prediction of transplant rejection in children
September 10th, 2014
by plexadmin
in
Events
General Articles

PITTSBURGH, Sept. 11, 2014 /PRNewswire-iReach/ -- Today the FDA announced approval of PleximmuneTM, a blood test from the Pittsburgh-based biotech company Plexision. This test predicts acute cellular rejection of transplanted livers and intestines in children. PleximmuneTM is a first-in-class test to determine a personalized rejection-risk index using cell-based technology.

The PleximmuneTM blood test predicts acute cellular rejection with an overall accuracy approaching or exceeding 80 percent in the 60-day period following the test. Test performance has been established in research blood samples from more than 200 children who received liver or intestine transplantation at the Children's Hospital of Pittsburgh of the University of Pittsburgh Medical Center

To read more please go to:
http://www.prnewswire.com/news-releases/fda-approves-pleximmunetm-for-pe...
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApp...

Related Posts

15
Nov

Plexision's PK/PD solutions presented at CHI's Immunogenicity Summit in Washington, DC - November 11, 2013.

Events
Plexision’s Pharmacokinetics (PK)/Pharmacodynamics (PD) solutions presented at Cambridge Healthtech Institute’s Immunogenicity Summit in Washington, DC on November 11, 2013.
7
Nov

Pleximmune test to predict liver transplant rejection presented at the Liver meeting in Washington DC - November 3, 2013.

Events
The Pleximmune test is the first blood test of its kind to predict whether acute cellular rejection will occur in children with liver or intestine transplantation. This information can help transplant physicians guide post-transplant care. During a six-year period, over two hundred and eighty blood samples from more than 200 children were tested in two groups. Samples from the first portion of the study period were termed the training set, and those obtained subsequently were termed the validation set.
22
Oct

American Transplant Congress, Seattle | 18–22 May 2013

Events
The American Transplant Congress was held between May 18-22 in Seattle this year. The American Transplant Congress is the premier venue for scientific exchange between the various disciplines uniquely involved in solid organ transplantation.
2
Aug

ESOT Congress, Vienna | Sept 8-11

Events
Optimizing the effectiveness of a new immnosuppressant requires usage, which is informed by an understanding of individual rejection-risk and response to the drug. This knowledge can facilitate the design of novel regimens based on the new immunosuppressant, and the selection of patients suited for such regimens.